A Phase II expansion trial to further explore NGM282's broad activity in biopsy-confirmed Nonalcoholic Steatohepatits (NASH).
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2017
At a glance
- Drugs NGM 282 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- 30 Oct 2017 New trial record